Alex Goldberg

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Mylan, Inc. (NASDAQ:MYL) Added to Equity Profile Report's NASDAQ Decliners Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 04/15/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Mylan, Inc. (NASDAQ:MYL).

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a biopharmaceutical company that focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders is currently down (-2.39%) on 2,177,966 shares traded after Baity Glenn who is VP AND GC at Acadia Pharmaceuticals, sold 30,000 shares at $12.83 per share for a total value of $384,800. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is currently down (-12.5%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Mylan, Inc. (NASDAQ:MYL) a company that engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients worldwide is currently down (-1.35%) on 1,303,997 shares traded after Mylan, Inc. Becomes #17 Most Shorted Nasdaq 100 Component, Replacing Regeneron Pharmaceuticals. Mylan, Inc. (NASDAQ:MYL) is currently down (-9.29%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Mylan, Inc. (NASDAQ:MYL)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com